Verona Pharma plc announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE – China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease.
Verona Pharma plc announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE – China Phase 3 trial for the maintenance treatment of chronic obstructive pulmonary disease.